Rina Hui
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
- Oncology 45
- Cancer Immunotherapy and Biomarkers 33
- HER2/EGFR in Cancer Research 5
- Cancer survivorship and care 3
-
- Breast Cancer Treatment Studies 18
- Co-authors
- Delvys Rodríguez‐Abreu (20 shared papers)Nir Peled (16 shared papers)Andrew George Robinson (13 shared papers)Katsuyuki Hotta (9 shared papers)Suman Rao (9 shared papers)Julie Renee Brahmer (10 shared papers)Sinead D. Cuffe (9 shared papers)Ali Tafreshi (10 shared papers)
- Journals
- Annals of Oncology (27 papers)Journal of Thoracic Oncology (20 papers)New England Journal of Medicine (7 papers)Journal of Clinical Oncology (6 papers)Lung Cancer (5 papers)
- Partner nations
- AustraliaUnited StatesSpain
In The Last Decade
Rina Hui
142 papers receiving 36.8k citations
Rina Hui's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 17.2k
- Pulmonary and Respiratory Medicine 6.5k
- Cancer Research 2.1k
- Otorhinolaryngology 189
- Immunology 549
Countries citing papers authored by Rina Hui
This map shows the geographic impact of Rina Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rina Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rina Hui more than expected).
Fields of papers citing papers by Rina Hui
This network shows the impact of papers produced by Rina Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rina Hui. The network helps show where Rina Hui may publish in the future.
Co-authors
The 25 scholars most cited alongside Rina Hui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 148 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 8221 |
| 2 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 5290 |
| 3 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 5289 |
| 4 | Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 3582 |
| 5 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2318 |
| 6 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Hit paper breakdown → | 2018 | 2246 |
| 7 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1302 |
| 8 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 849 |
| 9 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 817 |
| 10 | 2017 | 469 | |
| 11 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Hit paper breakdown → | 2023 | 441 |
| 12 | 2019 | 393 | |
| 13 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC Hit paper breakdown → | 2019 | 347 |
| 14 | Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial Hit paper breakdown → | 2017 | 291 |
| 15 | 2003 | 277 | |
| 16 | Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Hit paper breakdown → | 2024 | 277 |
| 17 | 2003 | 213 | |
| 18 | 2017 | 205 | |
| 19 | Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. | 1999 | 191 |
| 20 | 2020 | 174 |
About Rina Hui
Rina Hui is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Pharmacology, having authored 148 papers that have together received 37.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Treatments and Mutations (20 papers), Breast Cancer Treatment Studies (18 papers), Lung Cancer Diagnosis and Treatment (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (5 papers), HER2/EGFR in Cancer Research (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer survivorship and care (3 papers). The work is most often cited by research in Oncology (17.2k citations), Pulmonary and Respiratory Medicine (6.5k citations), Cancer Research (2.1k citations), Otorhinolaryngology (189 citations) and Immunology (549 citations). Rina Hui has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Delvys Rodríguez‐Abreu, Nir Peled, Andrew George Robinson, Katsuyuki Hotta, Suman Rao, Julie Renee Brahmer, Sinead D. Cuffe, Ali Tafreshi, Maya Gottfried and Tibor Csőszi. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, New England Journal of Medicine, Journal of Clinical Oncology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.